Combination Treatment With Paclitaxel, Carboplatin, and Cetuximab (PCE) as First-Line Treatment in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma

Combination Treatment With Paclitaxel, Carboplatin, and Cetuximab (PCE) as First-Line Treatment in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma

Background: Platinum-containing doublet chemotherapy regimens are generally considered the standard first-line systemic therapy for recurrent or metastatic (R/M) nasopharyngeal cancer (NPC). Gemcitabine (GEM) plus cisplatin (CDDP) has become a standard therapy based on a phase 3 study in several cou...

Full description

Bibliographic Details
Main Authors: Yuri Ueda, Tomohiro Enokida, Susumu Okano, Takao Fujisawa, Kazue Ito, Makoto Tahara
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-10-01
Series:Frontiers in Oncology
Subjects:
nasopharyngeal cancer (NPC)
PCE
paclitaxel
carboplatin
cetuximab
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.571304/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.571304/full

Similar Items